18 results on '"Oizumi, Satoshi"'
Search Results
2. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
3. First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
4. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
5. Clinicopathologic Features and Immune Microenvironment of Non–Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
6. Usefulness of Endobronchial Ultrasonography With a Guide Sheath and Virtual Bronchoscopic Navigation for Ground-Glass Opacity Lesions
7. Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study
8. Impact of symptom clusters on quality of life outcomes in patients from japan with advanced nonsmall cell lung cancers
9. First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study
10. Endobronchial Ultrasonography With a Guide Sheath in the Diagnosis of Benign Peripheral Diseases
11. Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations
12. Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer: West Japan Thoracic Oncology Group Study 0301
13. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)
14. Factors Related to Diagnostic Yield of Transbronchial Biopsy Using Endobronchial Ultrasonography With a Guide Sheath in Small Peripheral Pulmonary Lesions
15. A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L)
16. Perforin Is Required for Innate and Adaptive Immunity Induced by Heat Shock Protein Gp96
17. PD4-3-3: Phase II trial of carboplatin plus docetaxel combined with a selective cyclooxygenase-2 inhibitor (meloxicam) in first-line treatment of patients with advanced unresectable non-small cell lung cancer: anti-tumor effect and cyclooxygenase-2 expression
18. A5-05: Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in powerful therapeutic antitumor immunity to murine lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.